Pharma Stocks
-
Teva (NYSE:TEVA) Valuation in Focus as Analyst Upgrades and Innovation Strategy Boost Outlook
Teva Pharmaceutical Industries (NYSE:TEVA) stock has caught fresh attention as several analysts recently raised earnings estimates, citing encouraging data from…
Read More » -
Grippewelle Concerns Trigger Surge in Pharma Stocks as Germany Prepares
Germany’s flu season, known as “grippewelle,” is drawing heightened attention amidst predictions of a severe outbreak. This has spurred increased…
Read More » -
Vertex Pharmaceuticals (VRTX) Highlights Pipeline Progress at BofA Global Healthcare Conference
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best biotech stocks to buy. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) participated in the Bank…
Read More » -
AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?
Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results…
Read More » -
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%
Despite an already strong run, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares have been powering on, with a gain of 28% in…
Read More » -
Pharma Mar (BME:PHM) rises 8.0% this week, taking one-year gains to 106%
Unfortunately, investing is risky – companies can and do go bankrupt. But if you pick the right business to buy…
Read More » -
Danaher (DHR) Surges as Pharma Tariffs to Benefit Firm
We recently published 11 Stocks Crushing Wall Street With Whopping Gains. Danaher Corp. (NYSE:DHR) is one of the top performers…
Read More » -
GSK’s $30B US Gamble Sends Pharma Stocks Soaring After Trump Pricing Deal
This article first appeared on GuruFocus. GSK Plc (NYSE:GSK) is leaning harder into the United States, with outgoing CEO Emma…
Read More » -
Piramal Pharma Sees 12.33% Surge in Open Interest Amid Increased Trading Activity
Piramal Pharma Ltd has seen a significant rise in open interest, reaching 11,026 contracts, alongside a trading volume of 8,228…
Read More » -
These 4 Measures Indicate That Sotac Pharmaceuticals (NSE:SOTAC) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway’s Charlie Munger, Li Lu, makes no bones about it when he says…
Read More »